Targets all T cells which induces substantial lymphocyte depletion.
Both
Neither
Antithymocyte globulin (ATG):
Generalized immunosuppression associated with ATG administration may result in increased susceptibility to infection.
Clinical use includes prevention/treatment of kidney transplant rejection.
Both
Neither
ATG (antithymocyte globulin) complications:
Fever, headache
Cytokine release syndrome which obtains because of T-cell activation with release of T-cell cytokines.
Both
Neither
Anti-CD3 monoclonal antibodies:
CD3 is an element of the TCR (T-cell receptor) complex
and represent the target for the monoclonal anti-CD3 antibody.
Humanized, genetically altered anti-CD3 mAbs prevent binding to FC receptors.
Both
Neither
Teplizumab (Tzield):
FDA-approved (11/22): first drug delaying type I diabetes onset in at-risk patients.
Teplizumab:
although not preventative or curative for type I diabetes, this agent delays the requirement of exogenous insulin with its associated risks.
Both
Neither
Alemtuzumab (Lemtrada)
Classified as a depleting humanized anti-CD52 mAb
that is clinically used in treating organ transplantation issues and in chronic lymphocytic leukemia.
CD52 is described as the cluster of differentiation 52, glycoprotein encoded by the CD52 gene. CD52 is localized on the surface and mature lymphocytes and is associated with certain lymphoma types.
Both
neither
Alemtuzumab administration:
Binds to CD52 to a number of cell types such as B cells, T cells, macrophages et al.
Alemtuzimab binding to CD52 results in cell lysis which manifests as
a significant leukopenia that can last in excess of a year.
Both
Neither
Alemtuzumab (Lemtrada) clinical use/uses:
Induction of immunosuppressive treatment, permitting avoidance of initial high steroid dose administration.
Used in management of refractory acute cellular-as well as antibody-associated rejection.
Both
Neither
Neutropenia represents the most frequently observed adverse effect associated with alemtuzumab administration.
True
False
Another side effect associated with alemtuzumab administration is autoimmune hemolytic anemia.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e 2017 ls) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 54 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 A
Medical Pharmacology & Therapeutics 6e Elsevier 2022
